New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 28, 2014
09:59 EDTMGLN, VRTS, DYAX, SBNY, BCRX, NCI, EPEOn The Fly: Analyst Initiation Summary
Magellan Health (MGLN) initiated with a Market Perform at Leerink... Virtus Investment Partners (VRTS) initiated with a Neutral at BofA/Merrill... Signature Bank (SBNY) coverage resumed with a Buy at Goldman... Dyax (DYAX) initiated with an Outperform at Oppenheimer... BioCryst (BCRX) initiated with a Perform at Oppenheimer... Navigant Consulting (NCI) initiated with a Buy at UBS... EP Energy (EPE) initiated with an Equal Weight at Morgan Stanley.
News For MGLN;VRTS;DYAX;SBNY;BCRX;NCI;EPE From The Last 14 Days
Check below for free stories on MGLN;VRTS;DYAX;SBNY;BCRX;NCI;EPE the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 29, 2014
16:10 EDTDYAXDyax sees FY14 total revenue $61M-$66M, consensus $58.69M
FY14 estimates include KALBITOR net sales of $51M–$56M. Total top-line revenue guidance excludes royalties from CYRAMZA for which revenue is expected to be recognized, commencing in Q3. Operating costs and expenses are now expected to be in the range of $80M-$82M.
16:07 EDTDYAXDyax reports Q2 EPS (2c), consensus (5c)
Subscribe for More Information
07:17 EDTNCINavigant Consulting reiterates FY14 adjusted EPS view 94c-$1.06, consensus 99c
Subscribe for More Information
07:16 EDTNCINavigant Consulting reports Q2 adjusted EPS 22c, consensus 24c
Subscribe for More Information
July 28, 2014
16:21 EDTVRTSVirtus Investment Partners reports Q2 EPS with items $2.10, consensus $2.57
Subscribe for More Information
08:17 EDTMGLNMCO sell-off provides buying opportunity, says Leerink
Subscribe for More Information
July 25, 2014
06:44 EDTMGLNMagellan Health sees FY14 adjusted EPS $2.67-$3.32, consensus $2.40
Sees FY14 segment profit $238M-$258M; Sees FY14 cash flow from operations $204M-$226M
06:43 EDTMGLNMagellan Health reports Q2 adjusted EPS 39c, consensus 57c
Subscribe for More Information
July 23, 2014
08:05 EDTDYAXDyax announces publication of DX-2930 scientific data
Dyax announced the online publication of scientific data for DX-2930 in two peer-reviewed journals. Dyax, a biopharmaceutical company focused on hereditary angioedema (HAE) and other plasma-kallikrein-mediated disorders, is developing DX-2930 as a subcutaneous injection for prevention of HAE attacks. The first paper titled “A Phase 1 Study Investigating DX-2930 in Healthy Subjects” by Chyung et al. was published online in the Annals of Allergy, Asthma and Immunology. These data indicate that DX-2930 has a long half-life in humans and thus the potential for prophylactic inhibition of pKal activity for the therapeutic treatment of HAE. DX-2930 is now being evaluated in a Phase 1b study in patients with HAE. The second paper titled “Inhibition of Plasma Kallikrein by a Highly Specific, Active Site Blocking Antibody” by Kenniston et al. was published online in The Journal of Biological Chemistry. The paper describes the discovery and preclinical evaluation of DX-2930 as a long-acting inhibitor of pKal proteolytic activity. This paper is expected to appear in the September 2014 print issue of the journal. The company said, "These data, combined with data that will be obtained from the ongoing Phase 1b study, will inform and guide the future clinical development of DX-2930.”
July 22, 2014
05:40 EDTSBNYSignature Bank reports Q2 EPS $1.48, consensus $1.43
Subscribe for More Information
July 17, 2014
08:00 EDTNCINavigant Consulting initiated with a Market Perform at Barrington
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use